Advertisement

Topics

Assessing Risk Stratification Across Pivotal Prostate Cancer Trials

13:51 EST 8 Jan 2019 | OncLive

Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.

Original Article: Assessing Risk Stratification Across Pivotal Prostate Cancer Trials

NEXT ARTICLE

More From BioPortfolio on "Assessing Risk Stratification Across Pivotal Prostate Cancer Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...